Reminders

Changing Life Sciences Value Chain

Archives for August 2009 « Recent Articles

OfflinePhoto of Dr. Alan S. Louie

Betting on the Innovation Bootstrap from Recession

By Dr. Alan S. Louie

In reviewing recent news events, it was striking to note three separate articles that together highlight the treasures and troubles facing the life science industry, both today and in the future.  On the one hand, a report that surprising late stage results from Human Genome Sciences on their new lupus drug helped raise the company’s stock from $0.48 in March this year to more than $19 today (a > 4000% increase in less than 6 months).  On the other hand, a comparison of life science indus


OfflinePhoto of Eric Newmark

Pharmaceutical Companies Choke on Sales Data

By Eric Newmark – 8 Comments

A well known challenge for pharmaceutical companies is visibility into product sales and supply chain movement. Although the industry lacks item-level visibility (the root of industry visibility issues), pharmaceutical manufacturers actually have access to a tremendous amount of sales data and product movement-related information through both fee-for-service agreements (more specifically 867 data) and data delivery services such as IMS.  However, despite differences in the types of sales information th


OfflinePhoto of Dr. Alan S. Louie

Succeeding Despite the Noise: Spin = Reality?

By Dr. Alan S. Louie

The ongoing battle over healthcare reform has been enlightening as well as disappointing.  As a born and bred scientist, I would have hoped that as an informed society working towards common goals, discussions moving towards achieving basic healthcare for everyone in the United States would be based on rational options leading to success.  After all, we’re an innovative country of innovators and problem solvers capable of great things.  Presumably the rest of the world looks to us for t


OfflinePhoto of Eric Newmark

SupplyScape Acquired?

By Eric Newmark – 4 Comments

Serialization, pedigree, and authentication are among the most important transformations underway in the life sciences. Poor demand visibility, absent supply chain security, and revenue leakage in the channel are just a few of the several long standing inefficiencies within the industry that these technologies aim to fix. In a recent development, its appears that one of the leaders in the drug pedigree market, SupplyScape, has been acquired by a company called TraceLink, Inc, however few details about the a


OfflinePhoto of Dr. Alan S. Louie

Having attended the annual BIO meeting for years, it has always been clear that the life science (and greater health) industry is viewed as a major source of future investment, jobs, and revenue.  Beyond the existing regional powerhouses of Boston and the Bay Area, US states, including Iowa, Texas, and Florida, as well as countries around the world, including Ireland, Germany, Taiwan, and Malaysia are all actively seeking economic growth from the industry.  In reviewing this opportunity, there are



Viewed 707,109 times